Article directories Chiluen ShoesArticle directory marketing

Our company is an independent CRO based in the United States that conducts preclinical medicine toxicology in state-of-the art, GLP-certified research facilities in Eastern Europe. Our research sites are sponsored by the Ukrainian National Academy of Medical Sciences and Health Department and offer support for commercial development of new medicine discoveries as part of their core mission. The CRO was founded to bring the top-notch, lower cost services of these research sites to new bio-technology companies in the U.S. and Europe, thereby offering a smart option for promoting development programs quickly and at much lower cost than other commercial CROs. We provide a wide range of preclinical Contract Research Organization including drug safety, acute and chronic toxicity, pharmacological screening, bio-availability , bio-equivalence , and complete in vitro and in vivo screening for anti-cancer activity.

Our pre-clinical Contract Research Organization is able to price preclinical trials far below other CROs since we maintain a very low overhead in the U.S. and perform all studies in Kiev where labor and laboratory costs are much lower. Our staff in the U.S. consists only of the organization principals who deal directly with clients; we don’t have any promotion expenses aside from our website, and no head offices, supporting staff or other overhead to inflate costs. We have much lower research conduct prices in Kiev due to much lower labor rates and are able to provide our best rates for longer and more complex pre-clinical trials where labor is the greatest portion of the overall price. Because we utilize the same reliable international suppliers for animal models, reagents and lab materials as other Contract Research Organizations, we don’t have any cost advantage on these materials and thus less overall cost advantage for very short-term preclinical tests. But, regardless of your study protocol and length, our goal is to provide our clients the best possible value for their investment.